| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C Mumby, J R E Davis, J Trouillas, C E Higha. Phaeochromocytoma and Acromegaly: a unifying diagnosis. Endocrinology, diabetes & metabolism case reports. vol 2014. 2014-06-06. PMID:24897038. |
neuroendocrine tumours can stain positive for ghrh without coexisting acromegaly, but the resolution of patient symptoms and normalisation of serum gh and igf1 levels following surgery imply that this was functional secretion. |
2014-06-06 |
2023-08-13 |
Not clear |
| Trevor A Howlett, Debbie Willis, Gillian Walker, John A H Wass, Peter J Traine. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clinical endocrinology. vol 79. issue 5. 2014-05-08. PMID:23574573. |
we investigated the control of gh and igf1 in acromegaly in routine clinical practice in the uk on and off medical treatment. |
2014-05-08 |
2023-08-12 |
Not clear |
| A J Varewijck, A J van der Lely, S J C M M Neggers, S W J Lamberts, L J Hofland, J A M J L Jansse. In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life. Endocrine connections. vol 3. issue 2. 2014-04-16. PMID:24692508. |
a cross-sectional study was carried out in 15 patients with active acromegaly based on clinical presentation, unsuppressed gh during an oral glucose tolerance test, and elevated total igf1 levels (>+2 s.d.). |
2014-04-16 |
2023-08-13 |
human |
| K M J A Claessen, H M Kroon, A M Pereira, N M Appelman-Dijkstra, M J Verstegen, M Kloppenburg, N A T Hamdy, N R Biermas. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. The Journal of clinical endocrinology and metabolism. vol 98. issue 12. 2014-04-14. PMID:24081732. |
in active acromegaly, pathologically elevated gh and igf-1 levels are associated with increased bone turnover and a high bone mass, the latter being sustained after normalization of gh values. |
2014-04-14 |
2023-08-12 |
Not clear |
| D K Lüdecke, P A Crock, M Bidlingmaier, F Schupper. Novel use of endogenous GH-measurement directly after transsphenoidal microsurgery in acromegaly treated with pegvisomant. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 121. issue 8. 2014-04-02. PMID:23765756. |
the gh receptor antagonist pegvisomant is increasingly used as therapy in acromegaly. |
2014-04-02 |
2023-08-12 |
Not clear |
| Deborah Lidsky, Sarah Malacarne, Maria Mavromati, Bettina Köhler Ballan, Jacques Philipp. [News in endocrinology in 2013]. Revue medicale suisse. vol 10. issue 412-413. 2014-03-31. PMID:24558895. |
transsphenoidal surgery is the treatment of choice for acromegaly due to pituitary adenoma but it is not always possible to reduce or control tumor growth, inhibit gh hypersecretion and normalize igf-i. |
2014-03-31 |
2023-08-12 |
Not clear |
| Michèle d'Herbomez, Catherine Bauters, Christine Cortet-Rudelli, Didier Dewailly, Christine Docao, Jean-Louis Wémea. [Biomarkers in endocrinology]. Presse medicale (Paris, France : 1983). vol 43. issue 1. 2014-03-25. PMID:24342177. |
serum igf1 is a reliable measure of integrated gh concentrations in patients with acromegaly. |
2014-03-25 |
2023-08-12 |
Not clear |
| Subramanian Kannan, Laurence Kenned. Diagnosis of acromegaly: state of the art. Expert opinion on medical diagnostics. vol 7. issue 5. 2014-03-17. PMID:23971897. |
biochemical diagnosis of acromegaly relies on measurement of insulin-like growth factor-1 (igf-1) and growth hormone (gh). |
2014-03-17 |
2023-08-12 |
Not clear |
| Subramanian Kannan, Laurence Kenned. Diagnosis of acromegaly: state of the art. Expert opinion on medical diagnostics. vol 7. issue 5. 2014-03-17. PMID:23971897. |
an elevated igf-1 level above the age- and gender-specific normal range and nonsuppression of gh to oral glucose load to a nadir < 0.4 ng/ml in sensitive assays are currently considered diagnostic of acromegaly. |
2014-03-17 |
2023-08-12 |
Not clear |
| Dominic Cavlan, Shanti Vijayaraghavan, Susan Gelding, William Drak. GH replacement causing acute hyperglycaemia and ketonuria in a type 1 diabetic patient. Endocrinology, diabetes & metabolism case reports. vol 2013. 2014-03-11. PMID:24616775. |
a state of insulin resistance is common to the clinical conditions of both chronic growth hormone (gh) deficiency and gh excess (acromegaly). |
2014-03-11 |
2023-08-12 |
Not clear |
| Derya Burcu Hazer, Serhat Işık, Dilek Berker, Serdar Güler, Alper Gürlek, Taşkın Yücel, Mustafa Berke. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. Journal of neurosurgery. vol 119. issue 6. 2014-02-24. PMID:24074496. |
acromegaly is a disease that has significant morbidity and mortality related to high levels of growth hormone (gh) and insulin-like growth factor-i (igf-i), and is usually caused by pituitary adenomas. |
2014-02-24 |
2023-08-12 |
Not clear |
| F Tarhan, G Koç, N K Erdoğan, G Orü. Hand measurements in the follow-up of acromegaly. JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR). vol 96. issue 5. 2014-02-20. PMID:24479296. |
acromegaly is a chronic progressive disease that originates from the increased secretion of the insulin-like growth-hormone (igf-1) secondary to the hypersecretion of the growth hormone (gh). |
2014-02-20 |
2023-08-12 |
Not clear |
| Ling Wu, Sa V Ho, Wei Wang, Jianping Gao, Guifeng Zhang, Zhiguo Su, Tao H. N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior. International journal of pharmaceutics. vol 453. issue 2. 2014-02-11. PMID:23796830. |
growth hormone antagonist (gha), an analog of growth hormone (gh), can inhibit gh action and treat acromegaly. |
2014-02-11 |
2023-08-12 |
Not clear |
| Tove Lekva, Jens Petter Berg, Ansgar Heck, Stine Lyngvi Fougner, Ole Kristoffer Olstad, Geir Ringstad, Jens Bollerslev, Thor Uelan. Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery. PloS one. vol 8. issue 6. 2014-02-07. PMID:23825587. |
somatostatin analogs (sa) have been established as the first line medical treatment for acromegaly, but following long-term treatment, sa normalizes gh and igf-i levels in only 40-60% of patients. |
2014-02-07 |
2023-08-12 |
Not clear |
| Hai Sun, Jessica Brzana, Chris G Yedinak, Sakir H Gultekin, Johnny B Delashaw, Maria Fleseri. Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly. Journal of neurological surgery. Part B, Skull base. vol 75. issue 1. 2014-02-05. PMID:24498589. |
objectives to analyze surgical outcomes and predictive factors of disease remission in acromegaly patients who underwent microscopic transsphenoidal surgery (tss) for a growth hormone (gh)-secreting adenoma. |
2014-02-05 |
2023-08-12 |
Not clear |
| Ludovica F S Grasso, Rosario Pivonello, Annamaria Cola. Investigational therapies for acromegaly. Expert opinion on investigational drugs. vol 22. issue 8. 2014-02-04. PMID:23731031. |
the treatment of acromegaly aims at normalizing growth hormone (gh) and insulin-like growth factor (igf-i) levels and controlling tumor growth. |
2014-02-04 |
2023-08-12 |
Not clear |
| Marianne Anderse. Management of endocrine disease: GH excess: diagnosis and medical therapy. European journal of endocrinology. vol 170. issue 1. 2014-01-27. PMID:24144967. |
acromegaly is predominantly caused by a pituitary adenoma, which secretes an excess of gh resulting in increased igf1 levels. |
2014-01-27 |
2023-08-12 |
human |
| Marianne Anderse. Management of endocrine disease: GH excess: diagnosis and medical therapy. European journal of endocrinology. vol 170. issue 1. 2014-01-27. PMID:24144967. |
although the normalisation of gh and igf1 levels is the main objective in all patients with acromegaly, gh and igf1 levels may be discordant, especially during somatostatin analogue therapy. |
2014-01-27 |
2023-08-12 |
human |
| S Kohler, O Tschopp, L Sze, M Neidert, R-L Bernays, K-S Spanaus, P Wiesli, C Schmi. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values? General and comparative endocrinology. vol 188. 2014-01-17. PMID:23648743. |
monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-ghr) gene on "safe" gh cut-off values? |
2014-01-17 |
2023-08-12 |
Not clear |
| S Kohler, O Tschopp, L Sze, M Neidert, R-L Bernays, K-S Spanaus, P Wiesli, C Schmi. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values? General and comparative endocrinology. vol 188. 2014-01-17. PMID:23648743. |
acromegaly is an illness usually defined by excessively high growth hormone (gh) and insulin like growth factor 1 (igf-1) levels, the latter mainly reflecting gh action on the liver. |
2014-01-17 |
2023-08-12 |
Not clear |